Sanofi's
combination diabetes drug hits goal in second late-stage
trial
Send a link to a friend
[September 14, 2015]
PARIS (Reuters) - Sanofi said on
Monday a second late-stage Phase III study of its LixiLan diabetes drug
had met its main target, readying it for regulatory submissions by the
fourth quarter in the United States and the first quarter of next year
in the European Union.
|
LixiLan consists of a single-injection combination of Lyxumia, a
drug developed with Danish drugmaker Zealand Pharma, and Sanofi's
Lantus. It targets patients suffering from type 2 diabetes.
"Full results will be communicated in a future scientific forum,"
the French drugmaker said in a statement.
"The LixiLan-L Phase III clinical trial met its primary endpoint in
patients with type 2 diabetes treated with insulin glargine with or
without metformin. The fixed-ratio combination of insulin glargine
100 Units/mL and lixisenatide, a GLP-1 receptor agonist,
demonstrated statistically superior reduction in HbA1c (average
blood glucose over the previous three months) compared with insulin
glargine 100 Units/mL," it said.
In July, Sanofi said a first late-stage Phase III study of LixiLan
had shown satisfactory results.
Nearly 400 million people worldwide have diabetes, with type 2
accounting for more than 90 percent of cases. Without proper
treatment or lifestyle changes, those numbers are expected to grow
substantially in the coming years.
[to top of second column] |
![](../images/ads/current/Symphony_122313.png)
(Reporting by Matthias Blamont; Editing by Elaine Hardcastle)
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
![](http://archives.lincolndailynews.com/2015/Sep/14/images/ads/current/charrons_bch041713.png) |